000			02004 a2200553 4500
005			20250514165626.0
264		0	_c20040401
008			200404s 0 0 eng d
022			_a0008-5472
024	7		_a10.1158/0008-5472.can-3554-2 _2doi
040			_aNLM _beng _cNLM
100	1		_aBoulay, Anne
245	0	0	_aAntitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. _h[electronic resource]
260			_bCancer research _cJan 2004
300			_a252-61 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAnimals
650	0	4	_aDisease Models, Animal
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Administration Schedule
650	0	4	_aDrug Monitoring _xmethods
650	0	4	_aEverolimus
650	0	4	_aHumans
650	0	4	_aImmunosuppressive Agents _xadministration & dosage
650	0	4	_aLeukocytes, Mononuclear _xenzymology
650	0	4	_aMAP Kinase Signaling System _xdrug effects
650	0	4	_aMale
650	0	4	_aPancreatic Neoplasms _xdrug therapy
650	0	4	_aRats
650	0	4	_aRats, Inbred Lew
650	0	4	_aRibosomal Protein S6 Kinases, 90-kDa _xantagonists & inhibitors
650	0	4	_aSirolimus _xadministration & dosage
650	0	4	_aTime Factors
650	0	4	_aTumor Cells, Cultured
700	1		_aZumstein-Mecker, Sabine
700	1		_aStephan, Christine
700	1		_aBeuvink, Iwan
700	1		_aZilbermann, Frederic
700	1		_aHaller, Roland
700	1		_aTobler, Sonja
700	1		_aHeusser, Christoph
700	1		_aO'Reilly, Terence
700	1		_aStolz, Barbara
700	1		_aMarti, Andreas
700	1		_aThomas, George
700	1		_aLane, Heidi A
773	0		_tCancer research _gvol. 64 _gno. 1 _gp. 252-61
856	4	0	_uhttps://doi.org/10.1158/0008-5472.can-3554-2 _zAvailable from publisher's website
999			_c14455981 _d14455981